Mesenchymal stem cells suppress CaN/NFAT expression in the pulmonary arteries of rats with pulmonary hypertension

Experimental and Therapeutic Medicine

Volumn 10, Issue 5, 2015, Pages 1657-1664

  Liu, Junfeng ^a,b   Han, Zhibo ^c   Han, Zhongchao ^c   He, Zhixu ^a  

^a GUIZHOU MEDICAL UNIVERSITY   (China)

^b General Hospital of Huabei Oil Field   (China)

^c AmCellGene Co Ltd   (China)

Author keywords

Calcineurin; Mesenchymal stem cell; Model; Nuclear factor of activated T cells; Pulmonary hypertension; Transplantation

Indexed keywords

CALCINEURIN; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEMODYNAMICS; HISTOLOGY; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 84942238120     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2722     Document Type: Article

References (27)

1. Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N and Stenmark KR: Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 168: 659-669, 2006.
2. Hall S, Brogan P, Haworth SG and Klein N: Contribution of inflammation to the pathology of idiopathic pulmonary arterial hypertension in children. Thorax 64: 778-783, 2009.
3. Pinto RF, Higuchi ML and Aiello VD: Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts. Cardiovasc Pathol 13: 268-275, 2004.
4. Heath D and Edwards JE: The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 18: 533-547, 1958.
5. Perros F, Dorfmüller P, Montani D, Hammad H, Waelput W, Girerd B, Raymond N, Mercier O, Mussot S, Cohen-Kaminsky S, et al: Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 185: 311-321, 2012.
6. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, et al: Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122: 920-927, 2010.
7. de Frutos S, Spangler R, Alò D and Bosc LV: NFATc3 mediates chronic hypoxia-induced pulmonary arterial remodeling with alpha-actin up-regulation. J Biol Chem 282: 15081-15089, 2007.
8. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN and Michelakis ED: The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 104: 11418-11423, 2007.
9. Said SI, Hamidi SA and Gonzalez Bosc L: Asthma and pulmonary arterial hypertension: Do they share a key mechanism of pathogenesis? Eur Respir J 35: 730-734, 2010.
10. Rowlands DJ, Islam MN, Das SR, Huertas A, Quadri SK, Horiuchi K, Inamdar N, Emin MT, Lindert J, Ten VS, Bhattacharya S and Bhattacharya J: Activation of TNFR1 ectodomain shedding by mitochondrial Ca2+determines the severity of inflammation in mouse lung microvessels. J Clin Invest 121: 1986-1999, 2011.
11. Wu M, Han ZB, Liu JF, Wang YW, Zhang JZ, Li CT, Xin PL, Han ZC and Zhu XP: Serum-free media and the immunoregulatory properties of mesenchymal stem cells in vivo and in vitro. Cell Physiol Biochem 33: 569-580, 2014.
12. Yang ZX, Han ZB, Ji YR, Wang YW, Liang L, Chi Y, Yang SG, Li LN, Luo WF, Li JP, et al: CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties. PLoS One 8: e59354, 2013.
13. Le Blanc K, Rasmusson I, Sundberg B, Gӧtherstrӧm C, Hassan M, Unzel M and Ringdén O: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363: 1439-1441, 2004.
14. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G and Uccelli A: Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106: 1755-1761, 2005.
15. Baber SR, Deng W, Master RG, Bunnell BA, Taylor BK, Murthy SN, Hyman AL and Kadowitz PJ: Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 292: H1120-H1128, 2007.
16. Luan Y, Zhang X, Kong F, Cheng GH, Qi TG and Zhang ZH: Mesenchymal stem cell prevention of vascular remodeling in high flow-induced pulmonary hypertension through a paracrine mechanism. Int Immunopharmacol 14: 432-437, 2012.
17. Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, Han ZB, Xu ZS, Lu YX, Liu D, Chen ZZ and Han ZC: Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 91: 1017-1026, 2006.
18. Matsuda Y, Hoshikawa Y, Ameshima S, Suzuki S, Okada Y, Tabata T, Sugawara T, Matsumura Y and Kondo T: Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi 43: 283-288, 2005 (In Japanese).
19. Maruyama H, Watanabe S, Kimura T, Liang J, Nagasawa T, Onodera M, Aonuma K and Yamaguchi I: Granulocyte colony-stimulating factor prevents progression of monocrotaline-induced pulmonary arterial hypertension in rats. Circ J 71: 138-143, 2007.
20. Zangiabadi A, De Pasquale CG and Sajkov D: Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int 2014: 739674, 2014.
21. Patel R, Aronow WS, Patel L, Gandhi K, Desai H, Kaul D and Sahgal SP: Treatment of pulmonary hypertension. Med Sci Monit 18: RA31-RA39, 2012.
22. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S and Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 284: 143-147, 1999.
23. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL and Chen TH: Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 103: 1669-1675, 2004.
24. Fukuchi Y, Nakajima H, Sugiyama D, Hirose I, Kitamura T and Tsuji K: Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells 22: 649-658, 2004.
25. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP and Hedrick MH: Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng 7: 211-228, 2001.
26. Baksh D, Yao R and Tuan RS: Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells 25: 1384-1392, 2007.
27. Jun D, Garat C, West J, Thorn N, Chow K, Cleaver T, Sullivan T, Torchia EC, Childs C, Shade T, et al: The pathology of bleomycin-induced fibrosis is associated with loss of resident lung mesenchymal stem cells that regulate effector T-cell proliferation. Stem Cells 29: 725-735, 2011.